Table 1.

Recurrent symptoms reported in dose finding pilot study of icatibant⁴³

Patient age (years)/sex	Site of primary attack	Time after administration of icatibant of recurrence (hours)	Severity of recurrence	Site of recurrence
43F	Abdominal	14	Unknown	Abdominal
	Abdominal	17	Unknown	Abdominal
47M	Skin/abdominal	20	Mild	Skin/abdominal
31M	Skin/abdominal	20	Unknown	Skin
53F	Skin (foot)	27	Unknown	Skin (foot)